Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis
- Disease/Condition
- Trigger Finger
- Drug/Device/Intervention
- Triamcinolone Acetonide 40mg/mL
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- University of Missouri-Columbia
- Location
- Columbia, United States of America
- Phase
- Phase 4
- Start date
- Jun 25, 2019
- End date
- Jun 15, 2025
- Enrollment
- 200 participants
Green classification of trigger finger severity,Green classification of trigger finger severity,Green classification of trigger finger severity,Disabilities of the Arm, Shoulder and Hand (DASH),Disabilities of the Arm, Shoulder and Hand (DASH),Disabilities of the Arm, Shoulder and Hand (DASH),Pain Visual Analog Score (VAS),Pain Visual Analog Score (VAS),Pain Visual Analog Score (VAS),Upper Extremity Scores (PROMIS),Upper Extremity Scores (PROMIS),Upper Extremity Scores (PROMIS)
Trigger finger is a common cause of hand pain and dysfunction. Its due to chronic
 inflammation of the flexor tendon that leads to a pulley system mismatch. Historically it has
 been managed either conservatively with corticosteroid injections or through a surgical
 release of the A1 pulley. Several corticosteroids have been used for injection-
 dexamethasone, methylprednisolone, triamcinolone, betamethasone, paramethasone, etc. The
 purpose of out study is to determine if a 0.5 cc injection of Triamcinolone 40 mg/mL will be
 the most effective steroid injection for the non-surgical treatment. Approximately 200
 subjects will be enrolled and randomized to one of three treatment arms: Triamcinolone
 40mg/mL, Triamcinolone 10mg/mL and Soluble dexamethasone 4mg/mL. Treatment success will be
 defined as lack of conversion to surgical treatment, or no desire to proceed with surgery
 during study period (3 months).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04002037
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT04002037 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Missouri-Columbia and is currently Recruiting. The study focuses on Trigger Finger. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.